(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
11 April 2013 (11.04.2013)

WIPO | PCT

(10) International Publication Number
WO 2013/051936 A9

(51) International Patent Classification:
A61K 39/39 (2006.01)

(21) International Application Number:
PCT/NL2012/050694

(22) International Filing Date:
4 October 2012 (04.10.2012)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

2007536	5 October 2011 (05.10.2011)	NL
61/543,510	5 October 2011 (05.10.2011)	US
61/615,566	26 March 2012 (26.03.2012)	US

(71) Applicants: **ACADEMISCH ZIEKENHUIS LEIDEN LUMC** [NL/NL]; Albinusdreef 2, NL-2333 ZA Leiden (NL). **UNIVERSITEIT LEIDEN** [NL/NL]; Rapenburg 70, NL-2311 EZ Leiden (NL). **ISA PHARMACEUTICALS B.V.** [NL/NL]; Professor Bronkhorstlaan 10-92, NL-3723 MB Bilthoven (NL). **STICHTING TOP INSTITUTE PHARMA** [NL/NL]; Postbus 142, NL-2300 AC Leiden (NL). **STICHTING KATHOLIEKE UNIVERSITEIT** [NL/NL]; c/o Geert Grooteplein-Zuid 10, NL-6525 GA Nijmegen (NL).

(72) Inventors: **OSSENDORP, Ferdinand Antonius**; Oude Karselaan 104, NL-1182 CT Amstelveen (NL). **MELIEF, Cornelis Johannes Maria**; Wilhelminapark 33, NL-2012 KC Haarlem (NL). **KHAN, Selina**; Oude Rijn 124A, NL-2312HK Leiden (NL). **FILIPPOV, Dmitri Viktorovitsj**; Boerhaavelaan 182, NL-2334 EV Leiden (NL). **VAN DER MAREL, Gijsbert Arie**; Bronforel 13, NL-2318 MD Leiden (NL).

(74) Agent: **CRAMWINCKEL, Michiel**; Bezuidenhoutseweg 161, NL-2594 AG Den Haag (NL).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


Published:


— *with international search report (Art. 21(3))*

[Continued on next page]

(54) Title: ADJUVANT COMPOUND

Fig. 3





[1]

(57) Abstract: The invention is directed to a compound according to the formula [1] wherein R^1 and R^2 are branched or straight groups having up to 17 atoms selected from carbon, nitrogen, oxygen and sulphur, n is 0 to and including 18, Y is sulphur or selene, X is S or 0 and R is -OH or an organic group comprising one or more peptides, one or more nucleic acids, one or more antibodies or combinations thereof. The invention is also directed to process for preparing said compound and the use of said compound as an adjuvant. The invention is also directed to a composition comprising said compound and the use of said composition, for example as a vaccine composition.

WO 2013/051936 A9

— *with sequence listing part of description (Rule 5.2(a))*

(48) Date of publication of this corrected version:
12 September 2013

(15) Information about Correction:
see Notice of 12 September 2013